Onyx Pharma to Hold Call to Discuss Phase 3 DECISION Data at 2013 ASCO
Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today announced that it will hold a conference call to discuss data presented at an ASCO plenary session from the DECISION study, a Phase 3 trial investigating the use of Nexavar(R) (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine-refractory (RAI) differentiated thyroid cancer. The call will feature the principal investigator, Marcia Brose, M.D., Ph.D., Assistant Professor in the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania, and will include members of Onyx's management. Date: Monday, June 3, 2013 Time: 10:15 - 11:00 a.m. Central Time To access a live audio webcast of the conference call, log onto the company's website at: http://www.onyx.com/investors/event-calendar To access the live conference call, dial 847-585-4405 and use the passcode 34979134 #. A replay of the call will be available on the Onyx website or by dialing 630-652-3042 and using the passcode 34979134 # approximately one hour after the conference call concludes through June 17, 2013.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.